Minerva Neurosciences | NERV - Cash And Equivalent


Minerva Neurosciences reported $82.3M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Adma Biologics USD 138.15M 50.52M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025